Show simple item record

dc.contributor.authorFernández-Natal, I
dc.contributor.authorSaez-Nieto, Juan Antonio 
dc.contributor.authorMedina-Pascual, Maria Jose 
dc.contributor.authorAlbersmeier, A
dc.contributor.authorValdezate, Sylvia 
dc.contributor.authorGuerra-Laso, J M
dc.contributor.authorRodríguez, H
dc.contributor.authorMarrodán, T
dc.contributor.authorParras, T
dc.contributor.authorTauch, A
dc.contributor.authorSoriano, F
dc.identifier.citationNew Microbes New Infect . 2013 Dec;1(3):35-40.es_ES
dc.description.abstractDuring a 12-year period, Dermabacter hominis was isolated from 21 clinical samples belonging to 14 patients attending a tertiary hospital in León, Spain. Samples included blood cultures (14), peritoneal dialysis catheter exit sites (three), cutaneous abscesses (two), an infected vascular catheter (one) and a wound swab (one). Identification was made by API Coryne™ V2.0, Biolog™ GP2 and 16S rRNA gene amplification. Six febrile patients had positive blood cultures (one, two or three sets) and all of them were treated with teicoplanin (two patients), vancomycin, ampicillin plus gentamicin, amoxicillin/clavulanic acid and ciprofloxacin (one each). An additional patient with a single positive blood culture was not treated, the finding being considered non-significant. In the remaining seven patients the organism was isolated from a single specimen and three of them received antimicrobial treatment (ciprofloxacin, ceftriaxone plus vancomycin and amoxicillin/clavulanic acid). At least ten patients had several underlying diseases and conditions, and no direct mortality was observed in relation to the isolated organism. All isolates were susceptible to vancomycin, rifampin and linezolid. Resistance to other antibiotics varied: erythromycin (100%), clindamycin (78.5%), ciprofloxacin (21.4%) and gentamicin, quinupristin-dalfopristin, benzylpenicillin and imipenem 7.1% each. Thirteen isolates were highly resistant to daptomycin with MICs ranging from 8 to 48 (MIC90 = 32 mg/L); only one was daptomycin-sensitive (MIC = 0.19 mg/L).es_ES
dc.description.sponsorshipResearch Project GRS 698/A/11. Gerencia Regional de Salud. Junta de Castilla y León, Spain.es_ES
dc.publisherElsevier es_ES
dc.subjectAntimicrobial susceptibilityes_ES
dc.subjectDermabacter hominises_ES
dc.subjectClinical relevancees_ES
dc.subjectDaptomycin resistancees_ES
dc.titleDermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.contributor.funderJunta de Castilla y León (España) 
dc.identifier.journalNew microbes and new infectionses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/GRS 698/A/11es_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional